BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: López-Fraga M, Martínez T, Jiménez A. RNA interference technologies and therapeutics: from basic research to products. BioDrugs 2009;23:305-32. [PMID: 19754220 DOI: 10.2165/11318190-000000000-00000] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Wang C, Chen L, Huang Y, Li K, Jinye A, Fan T, Zhao R, Xia X, Shen B, Du J, Liu Y. Exosome-delivered TRPP2 siRNA inhibits the epithelial-mesenchymal transition of FaDu cells. Oncol Lett 2019;17:1953-61. [PMID: 30675260 DOI: 10.3892/ol.2018.9752] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
2 Wang S, Wei X, Sun X, Chen C, Zhou J, Zhang G, Wu H, Guo B, Wei L. A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system. Int J Nanomedicine 2018;13:617-31. [PMID: 29440889 DOI: 10.2147/IJN.S142797] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
3 Bergen J, Schaffer D. 4.33 Engineering Viruses For Gene Therapy. Comprehensive Biomaterials II 2017. [DOI: 10.1016/b978-0-08-100691-7.00167-1] [Reference Citation Analysis]
4 Arruda DC, Hoffmann C, Charrueau C, Bigey P, Escriou V. Innovative nonviral vectors for small-interfering RNA delivery and therapy. Nanostructures for Novel Therapy. Elsevier; 2017. pp. 713-40. [DOI: 10.1016/b978-0-323-46142-9.00026-8] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lusthaus JA, Goldberg I. Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma. Expert Opinion on Investigational Drugs 2016;25:1201-8. [DOI: 10.1080/13543784.2016.1223042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
6 Man DK, Chow MY, Casettari L, Gonzalez-Juarrero M, Lam JK. Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. Adv Drug Deliv Rev 2016;102:21-32. [PMID: 27108702 DOI: 10.1016/j.addr.2016.04.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
7 Sedaghati B, Hoyer J, Aigner A, Hacker MC, Schulz-siegmund M. Controlled Release Technologies for RNAi Strategies in Regenerative Medicine. Regenerative Medicine - from Protocol to Patient 2016. [DOI: 10.1007/978-3-319-28274-9_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Liang C, Guo B, Wu H, Shao N, Li D, Liu J, Dang L, Wang C, Li H, Li S, Lau WK, Cao Y, Yang Z, Lu C, He X, Au DW, Pan X, Zhang BT, Lu C, Zhang H, Yue K, Qian A, Shang P, Xu J, Xiao L, Bian Z, Tan W, Liang Z, He F, Zhang L, Lu A, Zhang G. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med 2015;21:288-94. [PMID: 25665179 DOI: 10.1038/nm.3791] [Cited by in Crossref: 189] [Cited by in F6Publishing: 200] [Article Influence: 23.6] [Reference Citation Analysis]
9 Ma Z, Yang C, Song W, Wang Q, Kjems J, Gao S. Chitosan hydrogel as siRNA vector for prolonged gene silencing. J Nanobiotechnology 2014;12:23. [PMID: 24946934 DOI: 10.1186/1477-3155-12-23] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
10 Martínez T, González MV, Roehl I, Wright N, Pañeda C, Jiménez AI. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther 2014;22:81-91. [PMID: 24025749 DOI: 10.1038/mt.2013.216] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 6.4] [Reference Citation Analysis]
11 Martínez T, Wright N, López-Fraga M, Jiménez AI, Pañeda C. Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet 2013;132:481-93. [PMID: 23494242 DOI: 10.1007/s00439-013-1288-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
12 Manskikh VN, Perelmuter VM. Collateral presentation of antigens as physiological prototype for lymph node metastases. Biochemistry Moscow 2013;78:314-23. [DOI: 10.1134/s0006297913030152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Pauley KM, Gauna AE, Grichtchenko II, Chan EK, Cha S. A secretagogue-small interfering RNA conjugate confers resistance to cytotoxicity in a cell model of Sjögren's syndrome. Arthritis Rheum 2011;63:3116-25. [PMID: 21567383 DOI: 10.1002/art.30450] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
14 Kaur IP, Sharma G. siRNA: A New Approach to Target Neuropathic Pain. BioDrugs 2012;26:401-12. [DOI: 10.1007/bf03261897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Tan M, Vernes J, Chan J, Cuellar TL, Asundi A, Nelson C, Yip V, Shen B, Vandlen R, Siebel C, Meng YG. Real-time quantification of antibody–short interfering RNA conjugate in serum by antigen capture reverse transcription–polymerase chain reaction. Analytical Biochemistry 2012;430:171-8. [DOI: 10.1016/j.ab.2012.08.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
16 Zhang L, Yang L, Li JJ, Sun L. Potential use of nucleic acid-based agents in the sensitization of nasopharyngeal carcinoma to radiotherapy. Cancer Letters 2012;323:1-10. [DOI: 10.1016/j.canlet.2012.03.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
17 Zhu X, Li H, Long L, Hui L, Chen H, Wang X, Shen H, Xu W. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai) 2012;44:519-26. [PMID: 22510476 DOI: 10.1093/abbs/gms026] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 8.1] [Reference Citation Analysis]
18 Simmons O, Maples PB, Senzer N, Nemunaitis J. Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease. ISRN Oncol 2012;2012:247657. [PMID: 22523703 DOI: 10.5402/2012/247657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
19 Zhang G, Guo B, Wu H, Tang T, Zhang BT, Zheng L, He Y, Yang Z, Pan X, Chow H, To K, Li Y, Li D, Wang X, Wang Y, Lee K, Hou Z, Dong N, Li G, Leung K, Hung L, He F, Zhang L, Qin L. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med. 2012;18:307-314. [PMID: 22286306 DOI: 10.1038/nm.2617] [Cited by in Crossref: 278] [Cited by in F6Publishing: 288] [Article Influence: 25.3] [Reference Citation Analysis]
20 Nemunaitis J, Rao DD, Liu SH, Brunicardi FC. Personalized cancer approach: using RNA interference technology. World J Surg 2011;35:1700-14. [PMID: 21557010 DOI: 10.1007/s00268-011-1100-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
21 Thakur N, Qureshi A, Kumar M. VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res 2012;40:D230-6. [PMID: 22139916 DOI: 10.1093/nar/gkr1147] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
22 Yeung ML, Jeang K. Roles of miRNAs in virus-mediated cellular transformation: lessons from human T-cell leukemia virus type 1. Future Virology 2011;6:1351-60. [DOI: 10.2217/fvl.11.109] [Reference Citation Analysis]
23 Zhang Y, Huang L. RNA Drug Delivery Approaches. Drug Delivery in Oncology 2011. [DOI: 10.1002/9783527634057.ch42] [Reference Citation Analysis]
24 Rousseau J, Escriou V, Lamoureux F, Brion R, Chesneau J, Battaglia S, Amiaud J, Scherman D, Heymann D, Rédini F, Trichet V. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res 2011;26:2452-62. [DOI: 10.1002/jbmr.455] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
25 Zhou C, Shan Y, Zhao H, He P. Biological effects of lentivirus-mediated shRNA targeting collagen type I on the mesangial cells of rats. Ren Fail 2011;33:334-40. [PMID: 21401360 DOI: 10.3109/0886022X.2011.559679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
26 Yeung ML, Jeang KT. MicroRNAs and cancer therapeutics. Pharm Res 2011;28:3043-9. [PMID: 21773853 DOI: 10.1007/s11095-011-0526-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
27 Ali Ashfaq U, Ansar M, Sarwar MT, Javed T, Rehman S, Riazuddin S. Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA. Virol J. 2011;8:112. [PMID: 21388559 DOI: 10.1186/1743-422x-8-112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
28 Bergen J, Schaffer D. Engineering Viruses For Gene Therapy. Comprehensive Biomaterials 2011. [DOI: 10.1016/b978-0-08-055294-1.00061-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Sarret P, Doré-savard L, Tétreault P, Bégin-lavallée V, Dansereau M, Beaudet N. Using RNA Interference to Downregulate G Protein-Coupled Receptors. Neuromethods 2011. [DOI: 10.1007/978-1-61779-179-6_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Méndez-Ortega MC, Restrepo S, Rodríguez-R LM, Pérez I, Mendoza JC, Martínez AP, Sierra R, Rey-Benito GJ. An RNAi in silico approach to find an optimal shRNA cocktail against HIV-1. Virol J. 2010;7:369. [PMID: 21172023 DOI: 10.1186/1743-422x-7-369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
31 Phalon C, Rao DD, Nemunaitis J. Potential use of RNA interference in cancer therapy. Expert Rev Mol Med. 2010;12:e26. [PMID: 20716384 DOI: 10.1017/S1462399410001584] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
32 Falschlehner C, Steinbrink S, Erdmann G, Boutros M. High-throughput RNAi screening to dissect cellular pathways: A how-to guide. Biotechnol J 2010;5:368-76. [DOI: 10.1002/biot.200900277] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
33 Grillari J, Grillari-Voglauer R. Novel modulators of senescence, aging, and longevity: Small non-coding RNAs enter the stage. Exp Gerontol 2010;45:302-11. [PMID: 20080172 DOI: 10.1016/j.exger.2010.01.007] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 6.3] [Reference Citation Analysis]
34 Coy S, Vasiljeva L. The exosome and heterochromatin : multilevel regulation of gene silencing. Adv Exp Med Biol 2011;702:105-21. [PMID: 21713681 DOI: 10.1007/978-1-4419-7841-7_9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
35 Journal Watch. Pharm Med 2009;23:331-348. [DOI: 10.1007/bf03256789] [Reference Citation Analysis]